July 1, 2019 / 5:26 AM / 3 months ago

BRIEF-Basilea Extends Phase 2 Study With Derazantinib In Intrahepatic Bile Duct Cancer

July 1 (Reuters) - BASILEA PHARMACEUTICA AG:

* BASILEA EXTENDS PHASE 2 STUDY WITH DERAZANTINIB IN INTRAHEPATIC BILE DUCT CANCER (ICCA) TO INCLUDE PATIENTS WITH FGFR2 GENE MUTATIONS OR AMPLIFICATIONS

* TOPLINE DATA FOR COHORT OF FGFR2 FUSION-POSITIVE PATIENTS ARE EXPECTED TO BE AVAILABLE AROUND MID-2020 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below